Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ReNeuron Group plc (RNUGF)
Pencoed, GB
ReNeuron Group plc is a UK-based biotechnology firm dedicated to the discovery, advancement, and eventual market launch of cutting-edge cell-based medical treatments. Their current pipeline features a CTX stem cell therapy, designed to improve outcomes for individuals suffering from stroke-related disabilities. Additionally, the company is progressing with its human retinal progenitor cell therapy, which is currently in Phase 2 clinical trials, aiming to address retinitis pigmentosa, a condition leading to blindness. Beyond these primary therapies, ReNeuron is also developing CTX-derived exosomes, which are microscopic packages of biological information released by CTX cells, and these are presently in the preclinical research stage. The company also offers licenses for its proprietary ReNcell product line. Demonstrating a commitment to collaborative research, ReNeuron has partnered with University College London to explore methods for generating immune cells from induced pluripotent stem cells, with the ultimate goal of developing novel anti-cancer cell therapies. Established in 1997, ReNeuron Group plc is headquartered in Pencoed, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -98.43% | -99.94% | -99.98% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%+31.5% ★ Q3'23: +170.7% (vs Q3'21)
-
EPS growth Biotechnology: +29.7%+44.3% ★ Q3'23: +46.0% (vs Q3'21)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,511.1% Q3'23: -1,338.2% (vs Q3'21)
-
EBIT margin Biotechnology: +0.0%-1,252.3% Q3'23: -2,101.9% (vs Q3'21)
-
ROIC Biotechnology: -16.1%— Q3'23: +503.1% (vs Q3'21)
-
Share dilution Biotechnology: -3.4%+0.3% ★ Q3'23: +0.5% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q3'23: -0.03× (vs Q3'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30.0K
est: 21.0K (+43.0%)
|
29.0K
est: 26.1K (+11.2%)
|
46.0K
est: 29.1K (+58.3%)
|
43.0K
est: 230.1K (-81.3%)
|
49.0K
est: 1.83M (-97.3%)
|
6.07M
est: 4.23M (+43.4%)
|
257.0K
est: 495.2K (-48.1%)
|
403.0K
est: 310.2K (+29.9%)
|
530.0K
est: 770.1K (-31.2%)
|
657.7K
est.
|
12.09M
est.
|
| EBITDA |
-10.27M
est: -21.0K (-48,848.9%)
|
-13.63M
est: -26.1K (-52,184.0%)
|
-19.72M
est: -29.1K (-67,759.7%)
|
-21.00M
est: -230.1K (-9,025.0%)
|
-17.70M
est: -1.83M (-865.5%)
|
-13.40M
est: -4.23M (-216.9%)
|
-13.00M
est: -495.2K (-2,525.0%)
|
-10.71M
est: -310.2K (-3,352.2%)
|
-6.37M
est: -770.1K (-727.2%)
|
-657.7K
est.
|
-12.09M
est.
|
| EBIT |
-10.39M
est: -21.0K (-49,444.8%)
|
-13.72M
est: -26.1K (-52,536.8%)
|
-19.89M
est: -29.1K (-68,341.3%)
|
-21.23M
est: -230.1K (-9,125.8%)
|
-17.20M
est: -1.83M (-838.2%)
|
-13.82M
est: -4.23M (-226.7%)
|
-13.38M
est: -495.2K (-2,601.8%)
|
-11.03M
est: -310.2K (-3,456.7%)
|
-6.64M
est: -770.1K (-761.9%)
|
-657.7K
est.
|
-12.09M
est.
|
| Net Income |
-8.91M
est: -27.51M (+67.6%)
|
-11.35M
est: -27.89M (+59.3%)
|
-15.57M
est: -36.17M (+56.9%)
|
-17.62M
est: -33.95M (+48.1%)
|
-14.29M
est: -30.89M (+53.7%)
|
-11.41M
est: -28.03M (+59.3%)
|
-11.35M
est: -18.90M (+40.0%)
|
-9.69M
est: -10.23M (+5.3%)
|
-5.41M
est: -7.17M (+24.6%)
|
-5.23M
est.
|
4.11M
est.
|
| SGA |
3.69M
est: 489.7K (+654.2%)
|
4.02M
est: 608.6K (+559.8%)
|
4.14M
est: 678.2K (+510.3%)
|
4.62M
est: 5.37M (-14.1%)
|
4.75M
est: 42.78M (-88.9%)
|
1.91M
est: 98.72M (-98.1%)
|
3.75M
est: 11.56M (-67.6%)
|
1.13M
est: 7.24M (-84.4%)
|
1.13M
est: 17.97M (-93.7%)
|
15.35M
est.
|
282.07M
est.
|
| EPS |
-0.48
est: -0.48 (+0.3%)
|
-0.42
est: -0.49 (+14.0%)
|
-0.48
est: -0.63 (+24.2%)
|
-0.54
est: -0.59 (+9.1%)
|
-0.44
est: -0.54 (+18.6%)
|
-0.35
est: -0.49 (+28.7%)
|
-0.29
est: -0.33 (+12.3%)
|
-0.17
est: -0.18 (+5.1%)
|
-0.09
est: -0.13 (+24.5%)
|
-0.09
est.
|
0.07
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Iain Gladstone Ross | Executive Chairman | 578.6K | male |
| John David Sinden | Co-Founder | 138.6K | — |
| Hadley Chilton | Secretary | — | male |
| Randolph Corteling | MD & Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RNUGF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
